Biotechnologies and Clusters in Paris Region Location : Maison Franco-Japonaise at Ebisu, auditorium Date : Monday 26 novembre 2001, from 13H30 to 17H Simultaneous translation English-Japanese Networking seminar coordinated by the EU-Japan Centre for Industrial Cooperation, Contact : Mr Fabrizio Mura (03 32 21 61 61) mura@eu-japan.gr.jp 13H30-14H : Registration 14H-14H10 : Biotechnologies and Clusters in Paris Region, Mr Thierry Mandon (President of Genopole, Vice-President of the Essonne County Council) 14H10-14H40 : Institut Pasteur : Licensing for Success by Jean-Pierre Saintouil Created in 1887 by Louis Pasteur, the Institut Pasteur is nowadays a private Research foundation which employs 5,400 scientists worldwide. The main Research focus and technologies involve: Pharmaceutical, Therapygenic, Drug delivery, Vaccines, Diagnostics, Genomic, Transgenic Mice and Biotechnology fields. A portfolio of 3,500 patents (330 priority patents) have been filed from the different technologies developped on the campus, including ones concerning HIV, HBV and Cold Probes. The presentation will describe the activity of the Business Development Department which contributed in 2000 to 44% of the budget of the Institut Pasteur. The objectives of the the Institut Pasteur delegates is meeting with Japanese companies in order to initiate contacts and future partnering in view of licensing technologies filed or issued in Japan by the Institut Pasteur. www.pasteur.fr Jean-Pierre Saintouil completed a Master Degree in Biochemistry and Genetics and a Degree in Strategic Business Management of the European School of Management (ESCP) Paris - France. His experience comprises 19 years of International sales, Marketing and Business Development in the Diagnostics Industry. Former Strategic Marketing Director for Sanofi Diagnostics Pasteur, Beckman and Bio-Rad; he is, since September 2000, the Director of the Office of Technology Transfer at Institut Pasteur. jpsaint@pasteur.fr 14H40-15H10 : NEUROTECH : Innovative Therapies for the Eye by Tom Shepherd Neurotech, the emerging biotechnological company in eye diseases, is focused on developing cell therapy products and protein delivery systems to treat major, vision-threatening eye disorders : retinal degenration such as age related macular degeneration or retinisis pigmentosa and vascular eye diseases such as diabetic retinopathy. www.neurotech.fr Dr. Tom Shepherd joined Neurotech in Paris as President and CEO in March 1998 and has successfully led Neurotech through two rounds of financing, (raising over ?50 million), a first IND filing and the establishment of a US R&D subsidiary. Prior to joining Neurotech, he held VP Business Development positions at IntraBiotics Pharmaceuticals and at ICN Pharmaceuticals in Southern California. Before moving to the USA, he was a Director of Cortecs PLC, a UK based drug delivery system company where he was responsible for marketing and licensing. He started his career in the Medical Department of Sandoz (now Novartis) in 1980. He has a Ph.D. in biochemistry from the University of Strathclyde in Scotland and successfully completed the Continuing Executive Program at the London Business School. t.shepherd@neurotech.fr 15H10-15H40 : New technologies for targeted recombination by Andre Choulika CELLECTIS is a rational genome engineering biotechnology company. Cellectis develops state of the art technologies to modify and rewrite any DNA sequence in any living organisms, including humans, animals, plants or insects. Based on principles of homologous recombination, Cellectis offers a wide array of technologies using Meganucleases. This novel class of DNA scissors allows precise modifications on cellular chromosomes, without adding any foreign DNA. Cellectis recombination technologies are based on a strong patent portfolio and know how such as the homologous recombination (patents issued in Japan). privilege applications are transgenics animal, protein production, and bioprocessed products. www.cellectis.com Dr Andre Choulika is the President and Chief Executive Officer of Cellectis. He has been a research associate at Pasteur Institute of Paris. He was a post doctoral fellow in the laboratory of Molecular Medicine, Harvard Medical School. He worked on Gene therapy, Development of new retroviral vectors, Sequencing and characterization of the protein PRP9. He has a Ph.D in Molecular Genetics, from the University Paris VI, and completed a MBA of the HEC School of Management. choulika@cellectis.com 15H40-15H55 : Coffee-break 15H55-16H15 : ED-partners, Networking for the biotech industry by Alain Schebath The Essonne Economic Agency and the Essonne Chamber of Commerce and Industry devised the Essonne Development initiative in order to pool all of the resources and partners needed for business establishment projects to succeed. The formation of this team allows the partners of Essonne Development to satisfy all the requirements of a business establishment project, in an efficient, welcoming environment. For each project, the partners undertake to provide : The services of a development agency: customized assistance and support, selection of sites, information on local economic resources through direct dialogue with the managers of already established companies (testimonials) and experienced service providers; The services of the Chamber of Commerce: formalities, business premises market, training, international expansion; Access to scientific expertise in a great many fields, such as genetics and genomics. www.ed-partners.org Alain Schebath holds a doctorate in town planning and urban development from the University of Paris-Val de Marne. After carrying out analyses of local finances, regional development policies, territorial marketing and urban management on behalf of BIPE-Conseil and BETURE-Conseil, he spent nearly 4 years in Japan as a guest researcher at the Yokohama National University. He is currently representing the Essonne Economic Agency. alain.schebath@ed-partners.org 16H15-16H35 : Genopole, the Biotech and Genetic Campus by Veronique Dufey GenopoleR is a research campus dedicated to Life Sciences (genetics, genomics and biotechnology), associating teaching, research and industry. The goal of GenopoleR and its Board of Directors is to help the decisions on biotechnology of France public research institutions (INRA, INSERM, CNRS, CEA), to establish research teams at Evry ; to contribute to the development of a high level educational center, and help the creation of biotechnology companies. Several industrial or service firms will benefit from the close proximity of a population of highly qualified researches in various fields of research in genetics and genomics. GenopoleR is also the head of a national network of genopoles. www.genopole.com Veronique Dufey holds a master's degree in Business Law and finished a specialization course in Finance. She joined the team of GenopoleR Industries as project manager in June 2001 offering a triple experience of a company. At the Banque de Developpement of SME, Veronique Dufey financed the investment programmes of industrial SME during five years. As from 1997, she set up one of the first companies specialized in the selection of waste on industrial sites. She worked during two years for the chamber of commerce and industry of Rennes as a consultant in the department of business development. veronique.dufey@genopole.com 16H35-16H55 : Invest in France Agency : France : the ideal place for R&D activities in Europe by Alexis Giloppe Alexis Giloppe holds a Master degree in international business at University Jean Moulin, Lyon 3 and a MBA from the Rennes Business school. He has been Project manager and office representative at Invest in France Agency Taiwan. He is actually Deputy to Asia representative, acting director of IFA at the French Embassy in Japan. datartok@gol.com 17H30-19H30 : Party at the restaurant l'Espace in the Maison Franco-Japonaise at the end of the networking seminar.